CD38 and plasma cell myeloma: The long physical half-life of 89Zr aligns with the extended biological half-life of monoclonal antibodies (~14 days in humans and ~7-8 days in mice), making 89Zr-daratumumab an ideal Cerenkov source for optimizing RaST and monitoring responses in CD38-overexpressing myeloma cells.